Related Experiment Video
Updated: Jul 20, 2026
08:01
Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis
Published on: November 17, 2017
New anti-inflammatory agents to reduce atherosclerosis
1Cardiology Division, Geneva University Hospital, Geneva, Switzerland. Francois.Mach@medecine.unige.ch
Archives of Physiology and Biochemistry
|August 26, 2006
Summary
Inflammation is key in atherosclerosis development. Anti-inflammatory treatments, including those targeting C-reactive protein (CRP) and cannabis compounds, show promise for managing cardiovascular diseases.
Area of Science:
- Cardiovascular Science
- Immunology
Background:
- Atherogenesis is increasingly understood to involve inflammatory processes.
- This understanding highlights the potential therapeutic role of anti-inflammatory agents.
Purpose of the Study:
- To review molecules relevant to atherosclerosis diagnosis, development, and treatment.
- Focus on C-reactive protein (CRP) and cannabis.
Main Methods:
- Literature review of inflammatory mechanisms in atherogenesis.
- Examination of C-reactive protein (CRP) and cannabis in relation to atherosclerosis.
Main Results:
- C-reactive protein (CRP) is a key biomarker and mediator in atherosclerosis.
- Cannabis compounds demonstrate potential anti-atherogenic and anti-inflammatory effects.
Conclusions:
- Inflammation is central to atherosclerosis, necessitating anti-inflammatory therapeutic strategies.
- C-reactive protein (CRP) and cannabis represent important targets for future cardiovascular disease management.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:38Inflammation
Overview
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...